Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASA“Children [and adolescents] are the living messages we send to a time we will not see,” but for the millions of children and adolescents with HIV, research and innovation are core to bringing this notion to reality through policy and public health practice. HIV is now a treatable chronic disease. Patients and families can set goals with health care practitioners to achieve undetectable and untransmissible viral load using antiretroviral therapy (ART), leading to improvements in both life expectancy and health-related quality of life. Pediatric research is needed to understand the impact of increasingly less cumbersome treatment regimens. There are opportunities to innovate treatments to address adverse effects, improve effectiveness, and ultimately enhance adherence. The recent meta-regression analysis by He et al in this issue of JAMA Pediatrics systematically evaluated the factors that contribute to child and adolescent HIV-related mortality from birth through age 14 years while being treated with ART in low-income countries. The aims of this study aims were to identify the gaps in modifiable risk factors known to reduce mortality in children and adolescents with HIV (eg, maternal education, access to food resources, clean drinking water, vaccination, and antibiotic prophylaxis to prevent opportunistic infections) that ART alone cannot address for optimal clinical and public health practice.